IP Verse

Anti-Ifnar1 Dosing Regime For Subcutaneous Injection

Patent No. EP4114465 (titled "Anti-Ifnar1 Dosing Regime For Subcutaneous Injection") was filed by Astrazeneca on Apr 21, 2022. The application was issued on Aug 30, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MAIWALDMay 29, 2024MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4114465

ASTRAZENECA
Application Number
EP22724683A
Filing Date
Apr 21, 2022
Status
Granted And Under Opposition
Jul 28, 2023
Publication Date
Aug 30, 2023
External Links
Slate, Register , Google Patents